The 13 most recent market catalysts affecting $WST, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 22, 2026
Corporate Catalyst
Bullish
Impact 75
West Pharmaceutical shares are trading higher after Morgan Stanley upgraded the stock from Equal-Weight to Overweight and raised its price target from $365 to $400.
The upgrade from Equal-Weight to Overweight and the increased price target from a major investment bank like Morgan Stanley signals a strong vote of confidence in West Pharmaceutic…
Sep 22, 2026
Corporate Catalyst
Bullish
Impact 65
Morgan Stanley Upgrades West Pharmaceutical Servs to Overweight, Raises Price Target to $400
Morgan Stanley analyst Kallum Titchmarsh upgraded West Pharmaceutical Services (WST) from Equal-Weight to Overweight and raised the price target from $365 to $400. This upgrade ind…
Sep 9, 2026
Corporate Catalyst
Bullish
Impact 65
UBS Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $415
UBS analyst Doug Schenkel maintained a 'Buy' rating on West Pharmaceutical Services (WST) and raised the price target from $340 to $415. This is a significant upgrade, indicating i…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 55
Citigroup Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $412
Citigroup analyst Joanne Wuensch maintained a 'Buy' rating on West Pharmaceutical Services and raised the price target from $400 to $412. This action signals continued analyst conf…
Jul 27, 2026
Corporate Catalyst
Bullish
Impact 55
Evercore ISI Group Maintains Outperform on West Pharmaceutical Servs, Raises Price Target to $425
Evercore ISI Group analyst Daniel Markowitz maintained an 'Outperform' rating on West Pharmaceutical Services (WST) and raised the price target from $410 to $425. This action signa…
Jul 23, 2026
Corporate Catalyst
Bullish
Impact 92
West Pharmaceutical CEO Highlights GLP-1 And Biologics Momentum
West Pharmaceutical Services (WST) significantly outperformed expectations in Q2 2026, reporting adjusted EPS and net sales well above consensus. This strong performance was primar…
Jul 23, 2026
Corporate Catalyst
Bullish
Impact 92
West Pharmaceutical Services shares are trading higher after the company reported better-than-expected Q2 financial results and issued Q3 guidance above estimates. Also, the company raised its FY26 guidance above estimates.
This headline represents a major corporate catalyst for West Pharmaceutical Services, driving its stock significantly higher. The better-than-expected Q2 results, coupled with stro…
Jul 23, 2026
Corporate Catalyst
Bullish
Impact 75
West Pharmaceutical Servs Raises FY2026 GAAP EPS Guidance from $8.15-$8.50 to $8.85-$9.05 vs $8.41 Est
West Pharmaceutical Services (WST) announced a significant upward revision to its FY2026 GAAP EPS guidance, moving from $8.15-$8.50 to $8.85-$9.05. This new range is notably higher…
Jul 23, 2026
Corporate Catalyst
Bullish
Impact 75
West Pharmaceutical Servs Raises FY2026 Adj EPS Guidance from $8.40-$8.75 to $8.85-$9.05 vs $8.61 Est; Raises FY2026 Sales Guidance from $3.295B-$3.350B to $3.345B-$3.380B vs $3.332B Est
West Pharmaceutical Services (WST) has filed an 8-K to announce an upward revision to its fiscal year 2026 adjusted EPS and sales guidance. The new EPS range of $8.85-$9.05 is sign…
Jul 23, 2026
Corporate Catalyst
Neutral
Impact 75
West Pharmaceutical Servs Sees Q3 Adj EPS $2.14-$2.24 vs $2.12 Est; Sees Sales $820.000M-$835.000M vs $815.707M Est
West Pharmaceutical Services (WST) has issued Q3 guidance projecting adjusted EPS of $2.14-$2.24, surpassing the analyst estimate of $2.12. Similarly, their sales forecast of $820.…
Jul 23, 2026
Corporate Catalyst
Bullish
Impact 92
West Pharmaceutical Servs Q2 Adj. EPS $2.37 Beats $2.08 Estimate, Sales $872.300M Beat $838.586M Estimate
West Pharmaceutical Services (WST) announced Q2 adjusted EPS of $2.37, significantly exceeding the $2.08 consensus estimate, and sales of $872.3 million, beating the $838.586 milli…
Jul 14, 2026
Corporate Catalyst
Neutral
Impact 55
West Pharmaceutical Services Enters Into Multiple Amended Distribution And Crosslicensing Agreements With Daikyo Seiko
West Pharmaceutical Services (WST) has formally extended its critical distribution and cross-licensing agreements with Daikyo Seiko for a further 10 years. This filing indicates th…
Jul 13, 2026
Corporate Catalyst
Neutral
Impact 65
BNP Paribas Initiates Coverage On West Pharmaceutical Servs with Outperform Rating, Announces Price Target of $447
BNP Paribas initiating coverage on West Pharmaceutical Services (WST) with an 'Outperform' rating and a $447 price target is a positive development for the company. Analyst initiat…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.